Drugs / Riboflavin-5-phosphate
Riboflavin-5-phosphate
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | BEROCCA PN | — | 1947-07-28 | fda.gov ↗ |
Trials 3 · a red edge is where a trial was stopped
194619471948194919501951195219531954195519561957195819591960196119621963196419651966196719681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05366933 | Aug 2022 → Jul 2027 expected | optic nerve disorder | National Aeronautics and Space Administration (NASA) | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00841386 | Sep 2008 → Dec 2011 | keratoconus | University at Buffalo | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03245853 | Jul 2017 → Sep 2019 | keratoconus | Comprehensive EyeCare of Central Ohio | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04708340 Comparator | Mar 2021 → Oct 2022 | COVID-19, acute respiratory distress syndrome | Reven Pharmaceuticals, Inc. | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04584125 Background | Jan 2027 → May 2028 expected | keratoconus | Joseph B. Ciolino, MD | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Riboflavin 5'-phosphate | “Active drug comprised of: ascorbic acid, magnesium sulfate heptahydrate, cyanocobalamin, thiamine, riboflavin 5' phosphate, niacinamide, pyridoxine, calcium d-pantothenate, and...” NCT04708340 ↗4“Vitamin B-Complex Supplement containing: 5-methyltetrahydrofolate, riboflavin 5 phosphate, pyridoxal phosphate, and methylcobalamin” NCT05366933 ↗ |
| Known as | Riboflavin | “Riboflavin 0.1% (10 mg riboflavin-5-phosphate in 10 ml dextran T-500 20% solution, supplied in a sterile, single dose container)” NCT00841386 ↗ |
| Known as | riboflavin phosphate | “instillation of 0.1% riboflavin phosphate-20% dextran T 500 solution at 5 minutes before UVA irradiation and every 5 minutes for a total of 30 minutes.” PMID 17457184 ↗ May 2007 |
| Modality | Other / unclassified | “daily nutraceutical supplement containing bioactive B vitamins” NCT05366933 ↗ |
| Route | Topical | “Riboflavin solution (0.1% riboflavin and 20% dextran supplied in a sterile, single-dose container) will be applied to the cornea every 2 minutes for 30 minutes.” NCT04584125 ↗ |